MESOBLAST LTD MESO

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue —$17.2M$5.9M$7.5M$10.2M$7.4M$32.2M$16.7M$17.3M$2.4M
Net income —-$102.1M-$88.0M-$81.9M-$91.3M-$98.8M-$77.9M-$89.8M-$35.3M-$76.8M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets —$784.7M$669.2M$669.4M$662.1M$744.7M$733.6M$652.1M$692.4M$655.7M
Short-term debt ————$5.0M$53.2M————
Total equity —$597.4M$480.4M$501.8M$497.0M$581.4M$549.3M$481.1M$546.0M$516.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001345099-26-000081.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total current liabilities
  • Goodwill
  • Total equity
  • R&D
Total current liabilities, Goodwill, Total equity, R&D by fiscal year, in US dollars The same figures are in the table below this chart. 0 200M 400M 600M Total equity, FY2017: 516.8M Total equity, FY2018: 546M Total equity, FY2019: 481.1M Total equity, FY2020: 549.3M Total equity, FY2021: 581.4M Total equity, FY2022: 497M Total equity, FY2023: 501.8M Total equity, FY2024: 480.4M Total equity, FY2025: 597.4M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Total current liabilities — — — — — — — — — —
Goodwill — — — — — — — — — —
Total equity $516.8M $546.0M $481.1M $549.3M $581.4M $497.0M $501.8M $480.4M $597.4M —
R&D — — — — — — — — — —

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B — -39.9%
RVMD Revolution Medicines, Inc. $45.01B — —
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B — 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%